Dual agonist

A dual agonist is one molecule engineered to switch on two different hormone receptors at once. In this category the term almost always means tirzepatide, which activates both the GIP receptor and the GLP-1 receptor. Its label describes exactly that, plus a structural detail worth knowing: a C20 fatty diacid chain that lets the molecule bind to albumin in the blood and stretches its half-life to about five days.

The logic behind stacking receptors is that appetite and metabolism are not controlled by a single switch. Hitting two pathways has, in practice, produced larger average weight reductions than hitting one. SURMOUNT-1 reported −20.9% average weight change at tirzepatide 15 mg over 72 weeks versus −3.1% on placebo, and the direct comparison against semaglutide in SURMOUNT-5 favored tirzepatide by about six and a half percentage points.

Not every dual agonist pairs GLP-1 with GIP. Survodutide combines GLP-1 with glucagon-receptor activity — which sounds backwards, since glucagon raises blood sugar, but glucagon also increases energy expenditure. In its 76-week trial, survodutide produced average weight changes of −12.2% and −13.0% at two doses versus −5.4% on placebo. CagriSema, by contrast, is a co-formulation of two separate molecules rather than a single dual agonist, which is a meaningful distinction when reading trial results.

The common misreading is that more receptors automatically means more weight loss. It means a different pharmacology with a different side-effect profile, and gastrointestinal complaints have generally scaled with efficacy across all of these agents. A triple agonist is not guaranteed to beat a dual one in the trials that actually matter.

Ask a clinician which receptors the drug you are being offered actually touches, and whether the distinction changes anything about your monitoring. Our pipeline review tracks the agents still in development.